



**Figure S1**




Kaplan-Meier curve comparing overall survival in patients with salivary gland adenoid cystic carcinoma of basal-like and indeterminate phenotypes. There was no significant difference.

Figure S2



Kaplan-Meier curve comparing overall survival in patients with salivary gland adenoid cystic carcinoma with MYB and MYBL1 rearrangements. There was no significant difference.

Figure S3



NFIB gene expression across various human tissues. NFIB is expressed in the highest level in minor salivary gland and breast.

**Table S1**

Clinicopathologic data and phenotypic profile of adenoid cystic carcinoma of salivary gland, lacrimal gland, and breast.

| Case/sex/age          | ER <sup>''</sup> | PR <sup>''</sup> | AR <sup>''</sup> | HER2 <sup>''</sup> | CK 5/6 <sup>''</sup> | EGFR <sup>''</sup> | Phenotypic profile* | PNI | Architectural grade <sup>''</sup> | Outcome, follow-up (months) |
|-----------------------|------------------|------------------|------------------|--------------------|----------------------|--------------------|---------------------|-----|-----------------------------------|-----------------------------|
| <b>Salivary gland</b> |                  |                  |                  |                    |                      |                    |                     |     |                                   |                             |
| 1/M/46                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | I                                 | NED 43                      |
| 2/M/31                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 248                     |
| 3/M/45                | -                | -                | -                | -                  | -                    | -                  | Indeterminate       | +   | NA                                | NED 204                     |
| 4/F/46                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 154                     |
| 5/M/66                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DM 18, NED 86               |
| 6/M/67                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DM 1, DOD 58                |
| 7/F/69                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | I                                 | DOC 120                     |
| 8/F/48                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | II                                | NED 77                      |
| 9/F/54                | -                | -                | -                | -                  | -                    | -                  | Indeterminate       | +   | II                                | LR 164+236, NED 281         |
| 10/F/83               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | III                               | DOD 1                       |
| 11/M/76               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DM 16, AWD 26               |
| 12/F/56               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 24                      |
| 13/F/62               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | I                                 | DM 92, AWD105               |
| 14/F/19               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | LR 127, DOD 155             |
| 15/M/67               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DOC 33                      |
| 16/F/52               | -                | -                | -                | -                  | -                    | +                  | Basal-like          | +   | II                                | NED 220                     |
| 17/F/14               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 107                     |
| 18/M/26               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 106                     |
| 19/F/68               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 65                      |
| 20/F/46               | -                | -                | -                | -                  | -                    | -                  | Indeterminate       | +   | I                                 | DM 30, AWD 78               |
| 21/F/53               | -                | -                | -                | -                  | -                    | -                  | Indeterminate       | +   | II                                | NED 37                      |
| 22/F/40               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | I                                 | NED 72                      |
| 23/M/47               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 246                     |
| 24/M/50               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 322                     |
| 25/F/53               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | II                                | NED 196                     |
| 26/F/75               | -                | -                | -                | -                  | +                    | +                  | Basal-like          | +   | II                                | DM 172, AWD 192             |
| 27/M/44               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | I                                 | LR 79, NED 122              |
| 28/M/71               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DM 21, DOD 27               |
| 29/F/44               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | NA  | I                                 | NED 92                      |
| 30/M/55               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DOD 108                     |
| 31/M/71               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | LR 17, DOD 36               |
| 32/F/81               | +                | -                | -                | -                  | -                    | -                  | Luminal             | +   | II                                | DM 13, DOD 16               |
| 33/F/54               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | III                               | NED 199                     |
| 34/F/40               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | II                                | NED 181                     |
| 35/F/32               | -                | -                | -                | -                  | +                    | +                  | Basal-like          | +   | II                                | NED 192                     |
| 36/F/83               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | NA  | I                                 | DOC 29                      |
| 37/M/67               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DOC 53                      |
| 38/M/47               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DM 81, DOD 110              |
| 39/F/48               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | III                               | LR 182, NED 186             |
| 40/M/32               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 101                     |
| 41/M/75               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DOC 166                     |
| 42/M/71               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | II                                | DOC 26                      |
| 43/M/65               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | I                                 | NED 26                      |
| 44/M/22               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 37                      |
| 45/M/69               | -                | -                | -                | -                  | +                    | +                  | Basal-like          | +   | II                                | NED 98                      |
| 46/F/43               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | III                               | NED 253                     |
| 47/M/71               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DOD 4                       |
| 48/F/63               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | I                                 | DM 55, DOD 100              |
| 49/M/56               | -                | -                | -                | -                  | -                    | -                  | Indeterminate       | +   | III                               | LR 7, DOD 15                |
| 50/F/65               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | III                               | DM 2, DOD 9                 |
| 51/F/81               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | II                                | DOC 86                      |
| 52/M/67               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | I                                 | DM 33, DOC 37               |
| 53/F/61               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | LR 139, NED 152             |
| 54/F/56               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | NA  | NA                                | LR 38, DOD 64               |
| 55/M/53               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 142                     |
| 56/F/48               | -                | -                | -                | -                  | -                    | -                  | Indeterminate       | +   | II                                | DM 64, DOD 190              |
| 57/F/55               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | I                                 | NED 72                      |
| 58/M/62               | -                | -                | -                | -                  | +                    | +                  | Basal-like          | +   | II                                | DM 10, DOD 16               |
| 59/M/49               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DM 34, DOD 92               |
| 60/M/55               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | NED 40                      |
| 61/M/68               | -                | -                | -                | -                  | -                    | -                  | Indeterminate       | +   | II                                | DM 32, DOD 56               |
| 62/F/53               | -                | -                | -                | -                  | -                    | -                  | Indeterminate       | +   | I                                 | DOC 6                       |
| 63/F/61               | -                | -                | -                | -                  | +                    | -                  | Basal-like          | -   | II                                | LR 6, DOD 86                |
| 64/M/56               | -                | -                | -                | -                  | +                    | +                  | Basal-like          | +   | III                               | NED 122                     |
| <b>Lacrimal gland</b> |                  |                  |                  |                    |                      |                    |                     |     |                                   |                             |
| Case/sex/age          | ER <sup>''</sup> | PR <sup>''</sup> | AR <sup>''</sup> | HER2 <sup>''</sup> | CK 5/6 <sup>''</sup> | EGFR <sup>''</sup> | Phenotypic profile* | PNI | Architectural grade <sup>''</sup> | Outcome (follow-up, months) |
| 1/M/67                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | LR 24, DOC 36               |
| 2/M/66                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | III                               | DM 60, DOD 108              |
| 3/F/32                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | +   | II                                | DM 216, AWD 234             |
| 4/F/57                | -                | -                | -                | -                  | +                    | -                  | Basal-like          | NA  | II                                | LR 12, DM 60, DOD 72        |

|               |                 |                 |                 |                   |                     |                   |                     |     |                                                                       |                             |
|---------------|-----------------|-----------------|-----------------|-------------------|---------------------|-------------------|---------------------|-----|-----------------------------------------------------------------------|-----------------------------|
| 5/F/23        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | +   | II                                                                    | LR 48, DM 60, DOD 64        |
| 6/M/41        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | +   | I                                                                     | LR 26, NED 150              |
| 7/M/41        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | NA  | II                                                                    | LR 36, DOD 123              |
| 8/F/24        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | +   | III                                                                   | DM 24, DOD 180              |
| 9/F/64        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | +   | II                                                                    | DOC 334                     |
| <b>Breast</b> |                 |                 |                 |                   |                     |                   |                     |     |                                                                       |                             |
| Case/sex/age  | ER <sup>+</sup> | PR <sup>+</sup> | AR <sup>+</sup> | HER2 <sup>+</sup> | CK 5/6 <sup>+</sup> | EGFR <sup>+</sup> | Phenotypic profile* | PNI | Architectural grade <sup>+</sup> /<br>Histological grade <sup>^</sup> | Outcome (follow-up, months) |
| 1/F/78        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | -   | II/II                                                                 | NED 146                     |
| 2/F/61        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | -   | I/I                                                                   | NED 81                      |
| 3/F/60        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | -   | I/I                                                                   | NED 82                      |
| 4/F/63        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | +   | II/III                                                                | NED 92                      |
| 5/F/81        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | -   | I/II                                                                  | NED 74                      |
| 6/F/72        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | +   | II/II                                                                 | NED 96                      |
| 7/F/53        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | -   | II/I                                                                  | DOC 92                      |
| 8/F/84        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | +   | III/III                                                               | NED 56                      |
| 9/F/53        | -               | -               | -               | -                 | +                   | -                 | Basal-like          | -   | II/II                                                                 | NED 62                      |
| 10/F/59       | -               | -               | -               | -                 | +                   | -                 | Basal-like          | -   | II/II                                                                 | NED 58                      |
| 11/F/71       | -               | -               | -               | -                 | +                   | -                 | Basal-like          | NA  | II/II                                                                 | NED 47                      |

One adenoid cystic carcinoma (case 32) was estrogen receptor (ER) positive, while progesterone receptor (PR), androgen receptor (AR) and HER2 was negative in all cases of all three locations. Luminal cells were positive for cytokeratin 5/6 (CK5/6) in 54/64 (84.4%), 9/9 (100%), and 11/11 (100%) of adenoid cystic carcinoma of salivary gland, lacrimal gland, and breast, respectively. Epidermal growth factor receptor (EGFR) was positive in 6/64 (9.4%) of salivary gland carcinomas and none in lacrimal gland and breast. Phenotypic profiles included basal-like in 55/64 (85.9%), indeterminate in 8/64 (12.5%) and luminal in 1 (1.56%) of salivary gland carcinomas. All adenoid cystic carcinomas in the lacrimal gland and breast were basal-like. Perineural invasion (PNI) was present in 9/62 (85.5%), 7/7 (100%), and 3/9 (33.3%) of evaluable salivary gland, lacrimal gland, and breast carcinomas. Architectural grade ranged from I-III in all three sites. Local recurrence (LR) occurred in 9/64 (14%), 5/9 (55.6%), and 0/11 patients with salivary gland, lacrimal gland, and breast carcinomas, respectively. Distant metastasis (DM) occurred in 16/64 (25%), 5/9 (55.6%), and 0% of salivary gland, lacrimal gland, and breast cases, respectively.

NED: No evidence of disease; DOC: Dead of other cause; AWD: Alive with disease; DOD: Dead of disease; NA= Not available.

“Positive when Allred score >2 (1). \* Assessed according to ASCO guidelines (2). <sup>#</sup>>10% of cells positive (1). Staining was most intense in abluminal cells. \*After Nielsen et al. (3) with addition of the luminal androgen receptor-positive phenotype described by DiPalma et al. (4). ^Nottingham grade (5). ^According to the grading systems proposed by Ro et al (6). ^2+ by immunohistochemistry and non-amplified with FISH. ^60% intensely positive, Allred 7.

1. Tan DSP, Marchiò C, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. *Breast Cancer Res Treat*. 2008;111(1):27–44.
2. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol* [Internet]. 2013;31(31):3997–4013. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24101045>
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res*. 2004;10(16):5367–74.
4. Di Palma S, Simpson RHW, Marchi?? C, Sk??lov?? A, Ungari M, Sandison A, et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. *Histopathology*. 2012;61(4):629–43.
5. Elston C, Ellis I. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology*. 1991;19(5):403–10.
6. Ro JY, Silva EG, Gallager HS. Adenoid cystic carcinoma of the breast. *Hum Pathol* [Internet]. W. B. Saunders Co.; 1987;18(12):1276–81. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2824330>

**Table S2**

Upregulated in salivary gland adenoid cystic carcinoma as compared to normal salivary gland

| ID                | Fold change | FDR                 |
|-------------------|-------------|---------------------|
| hsa-miR-1180-3p   | 1.98        | 0.0391076689233527  |
| hsa-miR-1273f     | 1.96        | 0.00604128455027582 |
| hsa-miR-4783-3p   | 1.95        | 0.0391076689233527  |
| hsa-miR-3187-3p   | 1.90        | 0.00604128455027582 |
| hsa-miR-6860      | 1.82        | 0.027956005694398   |
| hsa-miR-25-5p     | 1.81        | 0.0183850405301848  |
| hsa-miR-1972      | 1.77        | 0.00604128455027582 |
| hsa-miR-769-3p    | 1.71        | 0.0180747067437088  |
| hsa-miR-1183      | 1.70        | 0.0262468884502464  |
| hsa-miR-1273h-5p  | 1.63        | 0.0391093294885875  |
| hsa-miR-6796-5p   | 1.61        | 0.0493660655321969  |
| hsa-miR-877-5p    | 1.60        | 0.0403165808766103  |
| hsa-mir-3648      | 1.40        | 0.0250232271716401  |
| hsa-miR-455-5p    | 1.37        | 0.00485962984035479 |
| hsa-mir-612       | 1.33        | 0.0391076689233527  |
| hsa-miR-181d-5p   | 1.30        | 0.027956005694398   |
| hsa-mir-4688      | 1.26        | 0.0493660655321969  |
| hsa-miR-125b-1-3p | 1.25        | 0.0299571043685713  |
| hsa-miR-181c-3p   | 1.24        | 0.0262468884502464  |
| hsa-miR-4472      | 1.21        | 0.0391076689233527  |
| hsa-miR-483-5p    | 1.21        | 0.0230416551803923  |
| hsa-mir-4449      | 1.12        | 0.00604128455027582 |

Downregulated in salivary gland adenoid cystic carcinoma as compared to normal salivary gland

| ID              | Fold change | FDR                  |
|-----------------|-------------|----------------------|
| hsa-miR-148a-5p | 0.19        | 4.5547666867344e-06  |
| hsa-miR-138-5p  | 0.32        | 0.000128014014442403 |
| hsa-miR-885-5p  | 0.38        | 6.33346095424722e-05 |
| hsa-miR-466     | 0.46        | 0.0190260279047432   |
| hsa-miR-29c-3p  | 0.46        | 0.0236092633992817   |
| hsa-miR-139-5p  | 0.47        | 0.0391076689233527   |
| hsa-miR-5684    | 0.50        | 0.00214490590273304  |
| hsa-mir-4459    | 0.57        | 0.027956005694398    |
| hsa-miR-3935    | 0.58        | 0.0180747067437088   |
| hsa-miR-139-3p  | 0.59        | 0.0151813464825079   |
| hsa-miR-3127-3p | 0.59        | 0.0493660655321969   |
| hsa-miR-329-3p  | 0.63        | 0.0149380442367334   |
| hsa-mir-138-1   | 0.66        | 0.0363060304251899   |
| hsa-mir-4667    | 0.70        | 0.0363060304251899   |
| hsa-miR-5091    | 0.71        | 0.0180747067437088   |
| hsa-mir-4284    | 0.71        | 0.027956005694398    |
| hsa-mir-6791    | 0.71        | 0.0499955141183399   |

|                 |      |                      |
|-----------------|------|----------------------|
| hsa-mir-4318    | 0.74 | 0.00130041548227336  |
| hsa-mir-548o    | 0.74 | 0.0145869719820247   |
| hsa-mir-378e    | 0.74 | 0.0490060506454896   |
| hsa-mir-3116-2  | 0.76 | 0.0063457112320756   |
| hsa-mir-921     | 0.79 | 0.0262468884502464   |
| hsa-miR-6835-3p | 0.83 | 0.0460952279483584   |
| hsa-mir-711     | 0.89 | 0.0493660655321969   |
| hsa-miR-7704    | 0.94 | 6.36056032841803e-07 |

**Table S3**

Upregulated in lacrimal gland adenoid cystic carcinoma as compared to normal lacrimal gland

| ID                | Fold change | FDR                  |
|-------------------|-------------|----------------------|
| hsa-miR-455-5p    | 8.02        | 1.49030303257965e-06 |
| hsa-miR-181a-2-3p | 6.31        | 0.000352282226673189 |
| hsa-miR-93-3p     | 3.94        | 0.00181527323141286  |
| hsa-miR-181d-5p   | 3.54        | 0.026936739177417    |
| hsa-miR-106b-3p   | 2.89        | 0.00124752312040316  |
| hsa-miR-1307-5p   | 2.85        | 0.010903019215952    |
| hsa-miR-181a-5p   | 1.42        | 0.00436044641574018  |
| hsa-miR-93-5p     | 1.39        | 0.0395232018787364   |



**Table S4**

Upregulated in breast adenoid cystic carcinoma as compared to normal breast

| ID              | Fold change | FDR               |
|-----------------|-------------|-------------------|
| hsa-miR-183-3p  | 3.23        | 0.264824989559879 |
| hsa-miR-200a-5p | 2.89        | 0.264824989559879 |
| hsa-miR-93-3p   | 2.33        | 0.264824989559879 |
| hsa-miR-4428    | 2.24        | 0.264824989559879 |
| hsa-mir-93      | 1.66        | 0.264824989559879 |
| hsa-mir-4449    | 1.22        | 0.264824989559879 |

Downregulated in breast adenoid cystic carcinoma as compared to normal breast

| ID              | Fold change | FDR               |
|-----------------|-------------|-------------------|
| hsa-mir-1-1     | 0.72        | 0.264824989559879 |
| hsa-miR-548t-5p | 0.77        | 0.264824989559879 |
| hsa-mir-4634    | 0.80        | 0.264824989559879 |
| hsa-miR-3621    | 0.87        | 0.264824989559879 |
| hsa-miR-6789-5p | 0.90        | 0.264824989559879 |

**Table S5**

Functional annotation of microRNAs differentially expressed between adenoid cystic carcinoma of salivary gland and breast according to the Kyoto Encyclopedia of Genes and Genomes (KEGG)

| KEGG Pathway Name (KEGG ID)                                                        | KEGG orthology                      | Number of Genes Regulated by Differentially Expressed miRNAs | p value  |
|------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------------------------|----------|
| Fatty acid metabolism (hsa01212)                                                   | Metabolism                          | 36                                                           | 3.66e-8  |
| Steroid biosynthesis (hsa00100)                                                    | Lipid metabolism                    | 18                                                           | 3.03e-6  |
| Hippo signaling pathway (hsa04390)                                                 | Signal transduction                 | 103                                                          | 3.58e-6  |
| Neurotrophin signaling pathway (hsa04722)                                          | Nervous system                      | 92                                                           | 4.75e-8  |
| Lysine degradation (hsa00310)                                                      | Amino acid metabolism               | 38                                                           | 1.01e-5  |
| Protein processing in endoplasmic reticulum (hsa04141)                             | Folding, sorting and degradation    | 119                                                          | 1.01e-5  |
| Chronic myeloid leukemia (hsa05220)                                                | Cancers                             | 59                                                           | 1.28e-5  |
| TGF-beta signaling pathway (hsa04350)                                              | Signal transduction                 | 58                                                           | 3.31e-5  |
| Viral carcinogenesis (hsa05203)                                                    | Cancers                             | 134                                                          | 3.31e-05 |
| Fatty acid elongation (hsa00062)                                                   | Lipid metabolism                    | 18                                                           | 3.33e-5  |
| Pancreatic cancer (hsa05212)                                                       | Cancers                             | 52                                                           | <0.001   |
| Prion disease (hsa05020)                                                           | Neurodegenerative disease           | 21                                                           | <0.001   |
| Non-small cell lung cancer (hsa05223)                                              | Cancers                             | 44                                                           | <0.001   |
| Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate (hsa00532) | Glycan biosynthesis and metabolism  | 15                                                           | <0.001   |
| Biosynthesis of unsaturated fatty acids (hsa01040)                                 | Lipid metabolism                    | 16                                                           | <0.001   |
| Renal cell carcinoma (hsa05211)                                                    | Cancers                             | 50                                                           | <0.001   |
| Transcriptional misregulation in cancer (hsa05202)                                 | Cancers                             | 118                                                          | <0.001   |
| Colorectal cancer (hsa05210)                                                       | Cancers                             | 47                                                           | <0.001   |
| Bladder cancer (hsa05219)                                                          | Cancers                             | 31                                                           | <0.001   |
| MAPK signaling pathway (hsa04010)                                                  | Signal transduction                 | 166                                                          | 0.004    |
| Glycosaminoglycan biosynthesis - keratan sulfate (hsa00533)                        | Glycan biosynthesis and metabolism  | 12                                                           | 0.005    |
| Prolactin signaling pathway (hsa04917)                                             | Endocrine system                    | 51                                                           | 0.005    |
| Epstein-Barr virus infection (hsa05169)                                            | Infectious diseases                 | 137                                                          | 0.005    |
| Cell cycle (hsa04110)                                                              | Cell growth and death               | 85                                                           | 0.010    |
| Fatty acid biosynthesis (hsa00061)                                                 | Lipid metabolism                    | 9                                                            | 0.011    |
| RNA transport (hsa03013)                                                           | Translation                         | 111                                                          | 0.011    |
| Adherens junction (hsa04520)                                                       | Cellular community - eukaryotes     | 49                                                           | 0.013    |
| TNF signaling pathway (hsa04668)                                                   | Signal transduction                 | 73                                                           | 0.013    |
| Fatty acid degradation (hsa00071)                                                  | Lipid metabolism                    | 30                                                           | 0.014    |
| Thyroid hormone signaling pathway (hsa04919)                                       | Endocrine system                    | 83                                                           | 0.014    |
| ECM-receptor interaction (hsa04512)                                                | Signaling molecules and interaction | 59                                                           | 0.020    |
| Insulin signaling pathway (hsa04910)                                               | Endocrine system                    | 94                                                           | 0.020    |
| Estrogen signaling pathway (hsa04915)                                              | Endocrine system                    | 68                                                           | 0.020    |
| Signaling pathways regulating pluripotency of stem cells (hsa04550)                | Cellular community - eukaryotes     | 94                                                           | 0.020    |
| Thyroid hormone synthesis (hsa04918)                                               | Endocrine system                    | 46                                                           | 0.026    |
| Chagas disease (American trypanosomiasis) (hsa05142)                               | Infectious diseases                 | 69                                                           | 0.028    |
| Proteasome (hsa03050)                                                              | Folding, sorting and degradation    | 33                                                           | 0.033    |
| Legionellosis (hsa05134)                                                           | Infectious diseases                 | 39                                                           | 0.034    |
| HIF-1 signaling pathway (hsa04066)                                                 | Signal transduction                 | 70                                                           | 0.043    |
| Other types of O-glycan biosynthesis (hsa00514)                                    | Glycan biosynthesis and metabolism  | 19                                                           | 0.044    |